PL16: Straightforward Conversion of Peptides into Bioactive Lactam-Based Foldamers
PL09: Chemical Physiology of Antibody Conjugates and Natural Products
PL13: Complex Glycans in Health and Disease
PL18: Modulating Different Components of the Ubiquitin System with Small Molecules and Cyclic Peptides
PL07: The Influence of Free Ligand Conformations on Mcl-1 PPI Inhibition
PL12: Carbohydrate-Lectin Interactions - What Makes Them Unique?
PL03: Quo Vadis Small Molecule Cancer Therapeutics?
PL15: Identification of S 64315, a Potent and Selective Mcl-1 Inhibitor through Fragment-based Drug Discovery
PL11: Increasing Brain Exposure of Therapeutic Antibodies
PL04: Massively Multi-target Profile-QSAR: IC50 Predictions Comparable to 4-Concentration Experiments for most Novartis Assays
PL01: What Makes a Great Medicinal Chemist: Some Fresh Thoughts
PL19: Cysteine Arylation to Engineer, Deliver, and Discover Proteins
PL06: Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
PL17: Chemical Biology of mRNA Modifications
PL10: Click-Cleavable Antibody-Drug Conjugates
PL02: Reprogramming the Reactivity of Iron in Cancer
PL05: Automated Syntheses Planning and its Implications for Drug Design
PL20: Pierre Fabre Award Lecture - Click Chemistry with Mesoionics: New Tools for Chemical Biology
PL08: Paul Ehrlich Award Lecture - Chemotype - Phenotype - Target
PL14: Unlocking Drug Discovery Power through Collaborative Efforts between Academia and CRO : Bringing Novel Tankyrase Inhibitors towards the Clinic
KL01: Therapeutic Potential of Macrocyclic ALK2 Inhibitors
KL03: Nanofitin Modules Platform: Go Multispecific, Go Multiparatopic !
KL02: Tackling a Unique S1 Protease by SBDD - Highly Potent & Selective Factor D Inhibitors - Age-Related Macular Generation (AMD)
EFMC Sponsored Event